WallStSmart

Insmed Inc (INSM)vsNuvation Bio Inc (NUVB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 864% more annual revenue ($606.42M vs $62.90M). NUVB leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

NUVB

Avoid

31

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 7.8
Piotroski: 4/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

NUVB2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
633.0%10/10

Revenue surging 633.0% year-over-year

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

NUVB4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.49B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-53.2%2/10

ROE of -53.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : NUVB

The strongest argument for NUVB centers on Revenue Growth, Debt/Equity. Revenue growth of 633.0% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : NUVB

The primary concerns for NUVB are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while NUVB is a hypergrowth play — different risk/reward profiles.

NUVB carries more volatility with a beta of 1.51 — expect wider price swings.

NUVB is growing revenue faster at 633.0% — sustainability is the question.

NUVB generates stronger free cash flow (-30M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Nuvation Bio Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?